Cancer Cell Analysis Market Report 2025

The cancer cell analysis market size has grown strongly in recent years. It will grow from $10.44 billion in 2024 to $11.41 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. Growth in the historic period was driven by the rising prevalence of cancer, increased government funding for cancer research, stronger collaboration between research institutions and biotechnology companies, growing demand for liquid biopsy and other non-invasive testing methods, and the increasing need for personalized cancer therapies.

The cancer cell analysis market size is expected to see strong growth in the next few years. It will grow to $16.09 billion in 2029 at a compound annual growth rate (CAGR) of 9%. Growth in the forecast period is expected to be supported by rising demand for high-throughput analysis techniques, greater emphasis on early detection and screening, increasing focus on single-cell and rare cell studies, higher need for accurate clinical decision support, and wider adoption of digital pathology platforms. Key trends anticipated for the forecast period include the integration of AI in cancer cell imaging and analysis, advancements in next-generation sequencing platforms, adoption of multiplex biomarker detection assays, progress in immuno-oncology research tools, and greater use of bioinformatics and big data analytics to enable personalized therapy.

The increasing investments in cancer research are expected to propel the growth of the cancer cell analysis market in the coming years. As the global burden of cancer continues to rise, governments and private organizations are investing more funds into studies aimed at enhancing diagnostic methods and developing effective treatments. Cancer cell analysis is crucial to cancer research as it provides detailed insights into tumor biology, heterogeneity, and progression, allowing researchers to identify new biomarkers, evaluate treatment responses, and design targeted therapies. For example, the National Cancer Institute, a U.S.-based government agency, reported that the cancer research budget for the fiscal year 2024 was $7.2 billion, marking a 1.7% increase from the previous year. Therefore, the rising investments in cancer research will fuel the demand for cancer cell analysis technologies.

Key players in the cancer cell analysis market are focusing on innovations such as rare cell and circulating tumor cell (CTC) enrichment technologies to enhance cancer research and diagnostic capabilities. Rare cell and CTC enrichment involves isolating and capturing extremely low-frequency tumor cells from blood samples, which provide vital information about tumor heterogeneity, disease progression, and treatment responses. For example, in June 2024, Bio-Rad Laboratories Inc., a life science research and clinical diagnostics company based in the U.S., introduced Celselect Slides 2.0, an advanced microfluidic slide technology designed to improve rare cell and CTC capture with its Genesis Cell Isolation System. The updated version allows for 2.5 times more sample capacity per slide by increasing microchambers from 56,400 to 140,800. It also integrates seamlessly into existing workflows, boosting cancer research and enhancing the efficiency of cell analysis without requiring significant adjustments.

In February 2022, Labcorp, a U.S.-based diagnostics and healthcare company, acquired Personal Genome Diagnostics Inc. for $575 million. This acquisition is aimed at strengthening Labcorp’s oncology and cancer genomics portfolio by incorporating PGDx’s comprehensive liquid biopsy and tissue-based cancer cell analysis technologies. Personal Genome Diagnostics Inc., a U.S.-based company specializing in cancer cell analysis and genomics, offers advanced diagnostic solutions that support precision oncology and clinical decision-making.

Major players in the cancer cell analysis market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Merck KGaA, GE Healthcare Technologies Inc., Becton Dickinson and Company, Agilent Technologies Inc., Olympus Corporation, Illumina Inc., Sartorius AG, PerkinElmer Inc., Sysmex Corporation, Bruker Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Tecan Group Ltd., Miltenyi Biotec B.V. & Co. KG, Abcam plc, Promega Corporation, Creative Bioarray Inc., NanoCellect Biomedical Inc., Cell Biolabs Inc., Meiji Techno Co. Ltd.

North America was the largest region in the cancer cell analysis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer cell analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer cell analysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Cancer cell analysis is the comprehensive examination of cancer cells using laboratory and imaging techniques to understand their structure, behavior, and genetic profile. Its primary purpose is to support early detection, accurate diagnosis, and personalized treatment strategies for cancer patients. It also enables the study of tumor progression, evaluation of treatment responses, identification of biomarkers, and development of new therapies, thereby advancing precision oncology and improving patient outcomes.

The primary products and services in the cancer cell analysis market include reagents and consumables, instruments, accessories, software, and services. Reagents and consumables consist of essential chemical and biological materials used to detect and analyze cancer cells with accuracy. The types of analysis include genomic, proteomic, metabolomic, transcriptomic, and histopathological studies. Key technologies involve next-generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, flow cytometry, and immunohistochemistry (IHC). Applications cover biomarker discovery, drug development, precision medicine, clinical diagnosis, and research activities. End-users include pharmaceutical and biotechnology companies, hospitals and clinical laboratories, academic and research institutions, and others.

The cancer cell analysis market research report is one of a series of new reports that provides cancer cell analysis market statistics, including cancer cell analysis industry global market size, regional shares, competitors with a cancer cell analysis market share, detailed cancer cell analysis market segments, market trends and opportunities, and any further data you may need to thrive in the cancer cell analysis industry. The cancer cell analysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer cell analysis market includes revenues earned by entities by providing services such as consulting and research support services, data analysis and bioinformatics services, drug screening and efficacy testing, histopathology and digital pathology services, and clinical trial support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer cell analysis market also includes sales of digital pathology scanners, microfluidic devices, liquid biopsy kits, and immunohistochemistry (IHC) kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.